• Reported GAAP EPS of $0.06 • Reported revenue of $0.91M up 25.66% YoY
Bullish
IceCure Medical Ltd. achieved 26% global revenue growth and 35% gross profit increase, driven by strong North American ProSense adoption. Clinical acceptance improved with new guidelines and positive kidney cancer study results.
Bearish
IceCure Medical Ltd. faced increased R&D and G&A expenses, leading to a higher net loss of $4,274,000 and a decrease in cash. Sales in Asia also declined, partially offsetting global revenue growth.